Functional Interaction Between BRCA1 and DNA Repair in Yeast May Uncover a Role of RAD50, RAD51, MRE11A, and MSH6 Somatic Variants in Cancer Development

Luisa Maresca†, Samuele Lodovichi2,3†, Alessandra Lorenzoni2, Tiziana Cervelli2, Rossella Monaco1, Laura Spugnesi1, Mariella Tancredi1, Elisabetta Falaschi1, Katia Zavaglia1, Elisabetta Landucci1, Manuela Roncella1, Caterina Congregati6, Angiolò Gadducci7, Antonio Giuseppe Naccarato8, Maria Adelaide Caligo1* and Alvaro Galli2*

In this study, we determined if BRCA1 partners involved in DNA double-strand break (DSB) and mismatch repair (MMR) may contribute to breast and ovarian cancer development. Taking advantage the functional conservation of DNA repair pathways between yeast and human, we expressed several BRCA1 missense variants in DNA repair yeast mutants to identify functional interaction between BRCA1 and DNA repair in BRCA1-induced genome instability. The pathogenic p.C61G, p.A1708E, p.M775R, and p.I1766S, and the neutral p.S1512I BRCA1 variants increased intra-chromosomal recombination in the DNA-repair proficient strain RSY6. In the mre11, rad50, rad51, and msh6 deletion strains, the BRCA1 variants p.C61G, p.A1708E, p.M775R, p.I1766S, and the neutral p.S1512I did not increase intra-chromosomal recombination suggesting that a functional DNA repair pathway is necessary for BRCA1 variants to determine genome instability. The pathogenic p.C61G and p.I1766S and the neutral p.N132K, p.Y179C, and p.N550H variants induced a significant increase of reversion in the msh2Δ strain; the neutral p.Y179C and the pathogenic p.I1766S variant induced gene reversion also, in the msh6Δ strain. These results imply a functional interaction between MMR and BRCA1 in modulating genome instability. We also performed a somatic mutational screening of MSH6, RAD50, MRE11A, and RAD51 genes in tumor samples from 34 patients and identified eight pathogenic or predicted pathogenic rare missense variants: four in MSH6, one in RAD50, one in MRE11A, and two in RAD51. Although we found no correlation between BRCA1 status and these somatic DNA repair variants, this study suggests that somatic missense variants in DNA repair genes may contribute to breast and ovarian tumor development.

Keywords: BRCA1 missense variants, DNA repair genes, yeast based-functional assay, breast and ovarian cancer, somatic variants
INTRODUCTION

BRCA1 is a tumor suppressor gene that encodes a multi-domain protein of 1863 amino acid involved in a wide array of cellular pathways that maintain genomic stability, including DNA damage-induced cell cycle checkpoint activation, DNA damage repair, protein ubiquitination, higher chromatin hierarchical control as well as transcriptional regulation and apoptosis (Powell and Kachnic, 2003; Narod and Foulkes, 2004; Figure 1A). BRCA1 has been shown to localize at DNA double-strand break (DSB) sites and form nuclear foci with RAD51, an essential component of the homologous recombination (HR) (Scully et al., 1997a,b) and with MRE11A–RAD50–NBS1 (MRN complex), a DNA breakage sensor regulating DSB repair through both HR and non-homologous end joining (NHEJ) (Fu et al., 2003; Greenberg et al., 2006). Moreover, BRCA1 is a key component of a protein complex, termed BRCA1-associated genome surveillance complex (BASC) that contains tumor suppressors, DNA damage sensors and signal transducers, including MRN, the mismatch repair (MMR) proteins MLH1, MSH2, and MSH6, the Bloom syndrome helicase BLM, the ATM kinase, DNA replication factor C (RFC), and PCNA. The association of BRCA1 with MSH2 and MSH6 in the BASC complex also links BRCA1 to a sub-pathway of nucleotide excision repair (NER) that repairs base lesions in the transcribed DNA strand (Wang et al., 2000).

Germline BRCA1 pathogenic variants predispose to an increased lifetime risk of breast and ovarian cancer (Miki et al., 1994). Since the discovery of BRCA1, many mutations have been reported and classified which are associated with breast and ovarian cancer and cause the production of truncated and non-functional BRCA1 protein (Walker et al., 2013). In addition, many missense variants, named variants of unknown significance (VUS) have been identified (Carvalho et al., 2007). Their relationship to disease is more difficult to predict since the functional impact is not easily predictable. This may complicate the cancer risk assessment and affect the psychological state of carriers and relatives (Couch et al., 2008). The International Agency for Research on Cancer (IARC) proposed a five-class system-based classification of missense variants: Class 1 (not pathogenic or of no clinical significance), Class 2 (likely not pathogenic or of little clinical significance), Class 3 (uncertain), Class 4 (likely pathogenic), and Class 5 (definitely pathogenic) (Plon et al., 2008; Tavtigian et al., 2008a,b; Lindor et al., 2012; Valle et al., 2012). Functional assays have been developed to improve BRCA1 VUS classification (Radice et al., 2011; Millot et al., 2012).

Cancer-causing mutations in a tumor suppressor gene such as BRCA1 are expected to impair the protein’s biological activity. Even if mutations in BRCA1 give the higher susceptibility to develop breast cancer, several data suggest that this predisposition is dependent on a combination of several low penetrance factors (Fanale et al., 2012). Moreover, somatic mutations in DNA repair genes have been recently reported in several cancers including breast cancer (Chae et al., 2016; Nik-Zainal et al., 2016). Although mutations in DNA repair pathways that are functionally related to BRCA1 have been identified (Nik-Zainal et al., 2016), impact of these mutations on BRCA1 activity is very difficult to evaluate.

Although the single-cell model eukaryote Saccharomyces cerevisiae has no BRCA1 homolog, main DNA repair pathways are evolutionary conserved (Kowalczykowski, 2015; Groothuizen and Sixma, 2016). Recently, we created a web tool to help the construction of “humanized” yeast strains that could be useful to characterize cancer-associated missense variants (Mercatanti et al., 2017). Therefore, we used yeast as genetic model to investigate the functional interaction between BRCA1 missense variants and DNA repair and to address whether this model system could be useful to evaluate the cancer risk in patients carrying mutations in distinct DNA repair genes.

As the expression of BRCA1 cancer-related variants increased HR in yeast, we previously proposed the “yeast recombination assay” as reliable method to determine the functional impact of VUS (Caligo et al., 2009). Recently, we demonstrated in yeast that MSH2 affects BRCA1-induced HR and, in parallel, we found a high frequency (36%) of MSH2 somatic mutations in breast and ovarian tumors from BRCA1 missense variant carriers (Maresca et al., 2015). Taking advantage of the functional and sequence homology between human and yeast DNA repair genes (Sung et al., 2000; Liu et al., 2017), we determined whether the expression of several BRCA1 pathogenic and neutral variants in MSH6, RAD50, MRE11A, and RAD51 yeast deletion mutants affects HR. Moreover, we studied also the effect of BRCA1 variant expression on gene reversion in both MMR wild-type and defective yeast mutants. This could give some indication to understand the role of DNA repair in BRCA1-driven tumorigenesis.

Finally, to determine if BRCA1 partners involved in HR, NHEJ, and MMR may have a role in breast and ovarian cancer development, we performed a somatic mutational analysis by next generation sequencing (NGS) of MSH6, RAD50, MRE11A, and RAD51 genes in selected breast and/or ovarian tumors from BRCA1 missense variant carriers, BRCA1 mutation carriers, and BRCA1wt individuals.

MATERIALS AND METHODS

Plasmids, DNA Manipulation

All the plasmids carrying the BRCA1 variants contain the human BRCA1 cDNA under the yeast galactose inducible promoter GAL1p (Westmoreland et al., 2003). Details about the construction of the BRCA1 yeast expression plasmids have been already described (Caligo et al., 2009).

Yeast Strain

The haploid strain RSY6 of S. cerevisiae (a gift from Robert Schiestl, UCLA Los Angeles, CA, United States) has the following genotype: MATa ura3-52 leu2-3,112 trp5-27 ade 2-40 ilv1-92 arg4-3 his3Δ5′-pRS6-his3Δ3′ lys2-801 (Schiestl et al., 1988). RSY6 carries the two his3 alleles separated by the LEU2 marker and by the plasmid DNA sequence, one with a deletion at the 3′ end and the other with a deletion at the 5′ end, which

Frontiers in Genetics | www.frontiersin.org 2 September 2018 | Volume 9 | Article 397
were grown for 4–5 days at 30°C were selected in solid medium lacking uracil (SC-URA). Colonies transformants procedure described in Gietz and Schiestl (2007). Transformants acetate method with single strand DNA as carrier following the procedure described in Gietz and Schiestl (2007). Transformants were grown for 4–5 days at 30°C and further analyzed.

**Figure 1** | Effect of BRCA1 pathogenic and neutral missense variants on intrachromosomal recombination and gene reversion in Saccharomyces cerevisiae. (A) BRCA1 protein is composed by 1863 amino acids (aa) and consists of three main domains (RING, DNA binding, and BRCT domains) and a nuclear localization signal (NLS). Distribution of BRCA1 pathogenic (red), neutral (blue) variants, and VUS (black) tested in S. cerevisiae. The number of aa is reported above each functional domain. (B) The haploid strain RSY6 carries the two his3 alleles separated by the LEU2 marker and by the plasmid DNA sequence, one with a deletion at the 3' end and the other with a deletion at the 5' end, which share 400 bp of homology (blue box). An intrachromosomal recombination event leads to HIS3 reversion and loss of LEU2. (C) RSY6 and its derivative DSB repair mutants expressing the BRCA1 wt or missense variants were inoculated in galactose medium for 17 h at 30°C. As described in Section “Materials and Methods,” cells were counted and plated to score for survival and recombinants. Frequency of intra-chromosomal recombination reported in the vertical axis was expressed as HIS3 colonies per 10^6 vital cells. In the horizontal axis, the BRCA1 wt and the variants are reported. Data are reported as mean of four to five independent experiments ± standard deviation. Results were statistically analyzed using the Student’s t-test. *p < 0.05, **p < 0.01. (D) RSY6, msh2Δ, and msh6Δ mutants expressing the BRCA1 wt or missense variants were inoculated galactose medium for 17 h at 30°C. Intra-chromosomal HR was determined as described above. In the horizontal axis, the BRCA1 wt and the variants are shown. Data are reported as mean of four to five independent experiments ± standard deviation. Results were statistically analyzed using the Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001. (E) The strain RSY6 carries the ilv1-92 that allows the assessment of gene reversion to ILV1 by direct counting colonies grown in medium lacking isoleucine. (F) RSY6, msh2Δ, and msh6Δ mutants carrying BRCA1 expressing plasmids were inoculated in galactose medium for 17 h at 30°C. As described in Section “Materials and Methods,” cells were counted and plated to score for vital cells and revertants. Frequency of reversion was calculated as total number of ILV1 revertants per 10^6 vital cells. In the horizontal axis, the BRCA1 wt and the variants are reported. Data represents the mean of four to five independent experiments ± standard deviation. Results were statistically analyzed using the Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001.

Protein Extract Preparation and Western Blotting

BRCA1 protein level was determined in yeast cell extracts from RSY6 wild-type and DNA repair deletion mutants, transformed with the BRCA1 expression vector after 24-h induction in galactose medium. Single clones were pre-grown in 10–20 ml of SC-URA glucose medium for 24 h at 30°C. Then, cell pellet was washed in water, and split in two aliquots: one was inoculated in 20 ml of SC-URA glucose and the other one in 20 ml of SC-URA galactose. The cultures were incubated at 30°C for 17 h, under constant shaking. Thereafter, pellets were washed twice in ice cold water and re-suspended in 0.5 ml of suspension buffer [50 mM KCl, 5 mM MgCl₂, 0.1 M EDTA, 25 mM HEPES, 5 mM DTT, 0.3 M (NH₄)₂SO₄, 10% glycerol, pH 7.4] plus 10 μl of protease inhibitor solution (4.4 mg phenylmethylsulfonyl fluoride, 62 mg pepstatin, 50 mg chemostatin, and 725 ml DMSO in 1 ml H₂O). Total protein extracts were prepared according to the method reported in Maresca et al. (2015). BRCA1p is analyzed using Anti-BRCA1 MoAb Ab4 (clone SD118-Calbiochem). As loading control, we determined the level of the 3-phosphoglycerate kinase (PGK) with the anti-α3PGK antibody from Molecular Probes.
Yeast Recombination and Reversion Assay

The haploid RSY6 strain of *S. cerevisiae* and its isogenic mutants carrying deletion in *RAD50*, *RAD51*, *MRE11*, *MSH2*, or *MSH6* were used to evaluate the functional interaction between the BRCA1 missense variants and DNA repair. As previously reported, BRCA1 wt, four pathogenic (pC61G, p1708E, p1766S, and pM1775R), four neutral (pN132K, pY179C, pN550H, and pS1521I) BRCA1 missense variants, and one VUS (pA1789T) BRCA1 missense variants, and one VUS (pA1789T) BRCA1 were expressed in yeast by using yeast shuttle vector plasmid carrying the BRCA1 cDNA under the control of the galactose inducible promoter (Caligo et al., 2009; Maresca et al., 2015; Lodovichi et al., 2016; Figure 1A). The effect of BRCA1 wt and BRCA1 missense variants on intra-chromosomal HR frequency was evaluated in rad50Δ, rad51Δ, and mre11Δ mutants following the procedure already reported (Maresca et al., 2015). To determine the frequency of intra-chromosomal recombination, single colonies were inoculated into 5 ml of SC–URA-LEU medium and incubated at 30°C for 24 h. Thereafter, cultures were washed twice in sterile distilled water and counted. For each BRCA1 variant as well as the BRCA1 wt and the controls, aliquots containing 10^7 cells were inoculated in 5 ml of Synthetic Complete – uracil and leucine (SC–URA-LEU) – medium containing 5% galactose. In parallel, the same number of cells was inoculated in 5 ml of SC–URA-LEU glucose containing medium. Both glucose and galactose cultures were incubated at 30°C for 17 h under constant shaking. Thereafter, cells were washed twice counted and appropriate numbers plated onto complete medium to determine the number of vital cells, and onto solid medium lacking histidine. The frequency of intra-chromosomal recombination was calculated as total number of HIS3 colonies per 10^-4 vital cells. We have also determined the effect of BRCA1 on gene reversion at ilv1-92 allele (Figure 1E) in MMR-proficient RSY6 and in msh2Δ and msh6Δ mutant strains, by plating yeast-expressing BRCA1 wt or BRCA1 missense variants, grown at 30°C for 17 h in 5-ml SC–URA-LEU plus 5% galactose, in medium lacking isoleucine following the standard procedures; the frequency of reversion was calculated as total number of ILV1 revertants per 10^-6 vital cells (Zimmermann, 1975; Bronzetti et al., 1990b; Galli et al., 1991).

For each BRCA1 variant, a total number of four to six independent experiments were carried out. Results were statistically analyzed using the Student’s t-test.

Patients and Preparation of DNA Samples

For the somatic mutation screening of *MSH6*, *RAD50*, *MRE11A*, and *RAD51* genes, 34 patients belonging to hereditary breast and ovarian cancer (HBOC) families were enrolled. This work has been approved by the Ethical Committee for Human Clinical Studies at the University Hospital of Pisa. All patients underwent genetic counseling at the University Hospital of Pisa, Italy. Thirty-one were affected by breast cancer and three by ovarian cancer. Fourteen patients were carriers of BRCA1 variants (13 missense and one synonymous), eight carried pathogenic mutations in BRCA1 gene, and 12 were BRCA1 wt (Table 1). BRCA1 status of the patients is reported in Table 1. All patients tested negative for BRCA2 mutations. Histopathological and clinical features of patients such as tumor histotype, grade, and receptors status are reported in Supplementary Table S1.

DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples after manual microdissection to isolate the tumor area. For each patient, a blood sample was also available.

Libraries Preparation and NGS Sequencing

*MSH6* (NM_000179.2), *RAD50* (NM_005732.3), *MRE11A* (NM_133487.3), and *RAD51* (NM_005591.3) genes were screened for somatic mutations by NGS on ION Personal Genome machine™ (Thermo Fisher Scientific, Monza, Italy). To amplify the coding sequence and the exon–intron boundaries of the four genes, a custom panel of 163 primer pairs was designed using Ion AmpliSeq™ Designer software1. A target region of 12.07 kb was obtained, covering the 94% of the region of interest. Since FFPE DNA is often fragmented, the average length of each amplicon was 100 bp. Libraries preparation and sequencing were performed according to ion PGM protocol (Ion AmpliSeq™ Library Kit 2.0, Ion OT2™ 200 kit, and ion PGM™ Hi-Q™ Sequencing kit; Thermo Fisher Scientific, Monza, Italy; Spugnesi et al., 2016). For the high confidence detection of somatic mutations present at low frequencies in heterogeneous cancer samples and to obtain coverage of 800–1000×, DNA from eight patients were loaded on each 316 v2 chip. The primary data processing was carried out by Torrent suite v5.0.4 and Ion Torrent Variant Caller v5.0. High stringency quality somatic parameters were set: detection of single-nucleotide variants at MAF = 2% and insertions/deletions at MAF = 5%, BAM files were uploaded on Ion Reporter software v5.02 for variant annotation. Variants with p-value > 0.01 were discarded in order to avoid false positive variant calls. The p-value reported by the Ion Reporter software represents the probability that the variant call is incorrect.

Variants fulfilling the following filtering criteria were selected for further analysis:

- Coverage ≥ 800×
- MAF ≤ 1% (according to 1000 Genomes Project)
- Present in only one patient.
- Within 20 bp from exon-intron junction.
- VAF (variant allele frequency) ≥ 3%.

The pathogenicity of each filtered variant was predicted using SIFT, PolyPhen-2, Grantham score, and MutationTaster2 (Grantham, 1974; Kumar et al., 2009; Adzhubei et al., 2010; Schwarz et al., 2014). Moreover, for each filtered variant an extensive literature revision and of the major clinical and genetic databases (dbSNP, ClinVar, LOVD, and COSMIC) was performed, to integrate in silico and functional reports for each variant.

Note:

1. https://www.ampliseq.com/
2. https://ionreporter.thermofisher.com
TABLE 1 | BRCA1 status of patients.

| Patient | BRCA1 status | cDNA change | Protein change | Exon | Classification |
|---------|--------------|-------------|----------------|------|----------------|
| P063    | Missense variant | c.4484 G>T | p.R1495M | 14   | 1              |
| P258    | Missense variant | c.5365 G>A | p.A1789T | 22   | VUS            |
| P519    | Missense variant | c.536 A>G; c.648 A>C | p.Y179C; p.N550H | 8; 11 | 1              |
| P534    | Missense variant | c.3418 A>G | p.S1140G | 11   | 1              |
| P563    | Missense variant | c.2412 G>C | p.Q804H | 11   | 1              |
| P573    | Missense variant | c.4956 G>A | p.M1652I | 16   | 1              |
| P614    | Missense variant | c.3418 A>G | RS1140G | 11   | 1              |
| P628    | Missense variant | c.4484 G>T | p.D1546N | 15   | 1              |
| P648    | Missense variant | c.2521 G; c.3119 G>A | p.R841W; p.S1040N | 11   | 1              |
| P709    | Missense variant | c.3119 G>A | p.S1040N | 11   | 1              |
| P725    | Missense variant | c.4956 G>A | p.M1652I | 16   | 1              |
| P881    | Missense variant | c.2412 G>C | p.Q804H | 11   | 1              |
| P932    | Missense variant | c.3119 G>A | p.S1040N | 11   | 1              |
| P952    | Synonymous variant | c.591 C>T | p.C197C | 9    | 1              |
| P1002   | WT | – | – | – | – |
| P1003   | WT | – | – | – | – |
| P1027   | WT | – | – | – | – |
| P1040   | WT | – | – | – | – |
| P1049   | WT | – | – | – | – |
| P1051   | WT | – | – | – | – |
| P1052   | WT | – | – | – | – |
| P1103   | WT | – | – | – | – |
| P1120   | WT | – | – | – | – |
| P1143   | WT | – | – | – | – |
| P1207   | WT | – | – | – | – |
| P1223   | WT | – | – | – | – |
| P39     | MUT | c.3598del110 | – | 11 | Pathogenic mutation |
| P46     | MUT | c.3403del1A | – | 11 | Pathogenic mutation |
| P122    | MUT | c.5492delC | – | 24 | Pathogenic mutation |
| P194    | MUT | c.5035_5039delCTAAT | – | 17 | Pathogenic mutation |
| P325    | MUT | c.5266dupC | – | 20 | Pathogenic mutation |
| P358    | MUT | ex20A | – | 20 | Pathogenic mutation |
| P439p   | MUT | c.5035_5039delCTAAT | – | 17 | Pathogenic mutation |
| P485    | MUT | c.1388dupA | – | 11 | Pathogenic mutation |

BRCA1 missense variants are classified according to IARC (International Agency for Research on Cancer) from class 1 benign to class 5 certainly pathogenic as reported in Plon et al. (2008). BRCA1 missense variants tested in yeast deletion strains are reported in bold underlined.

According to functional studies in literature and bioinformatics prediction tools, a putative clinical significance was proposed. Variants were classified as follows:

- “Clearly pathogenic” (P): variants already reported in literature and databases as pathogenic.
- “ Probably pathogenic” (PP): variants never reported before and predicted pathogenic by two of the three major prediction tools interrogated (SIFT, PolyPhen2, and MutationTaster2).
- “Probably benign” (PB): variants never reported before and predicted benign by two of the three major prediction tools interrogated.
- “Clearly Benign” (B): variants already reported in literature and databases as benign.
- “Unknown”: no sufficient data available from literature, databases, and prediction tools.

Sanger sequencing was performed to confirm the identified variants. For each variant, Sanger Sequencing was also performed in lymphocyte DNA.

RESULTS

HR Induced by Pathogenic BRCA1 Variants in Yeast Is Abolished in DNA Repair Deletion Mutants

As the genetic pathways controlling DNA repair and recombination are basically conserved from yeast to humans, we used this microorganism in order to determine the functional relations between BRCA1 and DNA repair. We have previously reported that the expression of pathogenic BRCA1 missense variants increased intra-chromosomal HR both in haploid and
diploid yeast strain between two differentially deleted his3 alleles that share 400 bp homology leading to formation of HIS3wt with loss of LEU2 (Figure 1B; Caligo et al., 2009; Maresca et al., 2015). In the present study, we evaluated the effect of the expression of BRCA1wt and several missense variants (Figure 1A) on HR frequency, in yeast strains defective for the key players of HR, NHEJ, and MMR to assess which pathways may affect the BRCA1-induced genome instability. Therefore, the following strains were used: the HR defective strains RSY6rad51Δ, the NHEJ defective strains RSY6 mre11Δ and RSY6rad50Δ, and the MMR defective strain RSY6msh6Δ. Results from RSY6 and msh2Δ strain have been partially published and are reported here for comparison (Maresca et al., 2015).

Previously, we reported that our yeast strains are able to sustain BRCA1 expression driven by a galactose inducible promoter; moreover, in the RSY6msh2Δ strain, all the BRCA1 missense variants used in this study are expressed at comparable level (Caligo et al., 2009; Maresca et al., 2015; Lodovichi et al., 2016). Here, we confirmed that each yeast strain expressed the 220 kDa BRCA1 wt protein and the BRCA1 missense variants (Supplementary Figure S1). The expression of the pathogenic p.C61G, p.A1708E, p.M775R, and p.I1766S, and the neutral p.S1512I BRCA1 variant induced a statistically significant increase of intra-chromosomal HR in RSY6 strain as compared to BRCA1wt (Figure 1C). The expression of the BRCA1 wt, the neutral variants p.N132K, p.Y179C, and p.N550H, and the VUS p.A1789T did not induce intra-chromosomal recombination in the DNA repair-proficient RSY6 strain (Figure 1C). Previously, we reported that the expression of neutral variants p.N132K and p.Y179C induced a statistically significant increase in HR in the diploid yeast strain RS112; this effect is much weaker than the effect induced by the pathogenic variants (Caligo et al., 2009). This may suggest that the haploid strain RSY6 could be more reliable than the diploid strain to discriminate between pathogenic and neutral variants. In general, we confirmed that yeast is a good model to discriminate pathogenic BRCA1 variants from neutral polymorphisms. In the mre11, rad50, and rad51 deletion strains, the expression of BRCA1 variants p.C61G, p.A1708E, p.M775R, p.I1766S, and p.S1215I did not increase intra-chromosomal HR (Figure 1C); this suggests that a functional DNA DSB repair pathway is necessary for BRCA1 pathogenic variants to determine its effect on HR. These results do not allow us to understand the precise mechanism by which BRCA1 pathogenic variants increased HR in yeast. We could speculate that the pathogenic variants could interfere with the “recombination machinery” leading to an accumulation of “intermediate” recombination substrates that could determine a high level of DSB that could be responsible to the HR effect. A similar effect was seen when the human MMR protein MSH1 was expressed in yeast (Shimodaira et al., 1998). Consequently, in the DSB repair deletion strains mre11, rad50, and rad51 no effect on HR was induced by BRCA1 variants indicating that these DNA repair functions are required for BRCA1-induced HR.

In yeast and other eukaryotes, defects in MMR genes also affect HR (Flores-Rozas et al., 2015; Chakraborty and Alani, 2016). Moreover, inactivation of MMR genes such as MSH2 and MSH6 determines an increase of resistance to anticancer drugs that depends on HR (Durant et al., 1999). This confirms a functional interplay between HR and MMR. In the RSY6msh2 deletion strain, the expression of BRCA1wt and several missense variants increased intra-chromosomal HR with respect to the negative control (pYES2), as already reported (Figure 1D; Maresca et al., 2015). On the other hand, in the RSY6msh6 strain BRCA1 variants had no effect on intra-chromosomal HR indicating that this MMR function is required to BRCA1 variants to determine the effect on HR.

Expression of BRCA1 Variants Induced Gene Reversion in RSY6 Strain and MMR Mutants

As MMR defects are related to a general increase in gene mutation (Bak et al., 2014), we have determined the effect of BRCA1 expression on yeast gene reversion in MMR-proficient RSY6 and in the MMR defective msh2 and msh6 deletion mutants. We have used the ilv1-92 reversion assay because it is one of the most used reversion tests (Figure 1E; Zimmermann, 1975; Bronzetti et al., 1990a; Galli et al., 1991). The expression of the pathogenic p.M1775R, p.I1766S, and neutral p.N132K variants induced a statically significant increase of gene reversion as compared to BRCA1wt in RSY6 strain (Figure 1F). The pathogenic p.C61G and p.I1766S and the neutral p.N132K, p.Y179C, and p.N550H variants induced a significant increase of reversion in the RSY6 msh2 deletion strain (Figure 1F); the neutral p.N132K and the pathogenic p.I1766S variant induced ILV1 reversion also in the RSY6msh6 (Figure 1F). Moreover, in the msh6Δ mutant, the expression of the VUS p.A1789T increased gene reversion (Figure 1F). These results indicate that MMR could affect BRCA1-induced genome instability. We could hypothesize that the expression of the BRCA1 missense variant when MMR is defective affects DNA replication fidelity as previously reported (Powell and Kachnic, 2003).

Identification of DNA Repair Gene Missense Variants in Tumor Samples

BRCA1-mutated breast cancers have been reported to show genome instability mainly due to the defect in DSB repair (Kwei et al., 2010). Previously, we found a high frequency of MSH2 missense variants in BRCA1 VUS carrier patients suggesting a role of MMR in BRCA1 tumorigenesis (Maresca et al., 2015). We thought to screen tumor samples to address whether other DNA repair genes may be related to BRCA1 defective cancers. In this study, 34 patients from HBOC families were enrolled: 31 affected by breast cancer and three by ovarian cancer. The histopathological and clinical features of all patients are reported in Supplementary Table S1. A total of 14 patients carried BRCA1 variants (13 missense and one synonymous), eight carried BRCA1 pathogenic mutations, and 12 patients were BRCA1wt. The classification of the BRCA1 missense variants and the type of BRCA1 mutations found in the patients were reported in Table 1. Most BRCA1 missense variants are classified not pathogenic (IARC class 1). Therefore, we can determine whether the presence of mutations in genes other than BRCA1 could have a role in HBOC. Mean age at diagnosis was approximately
40 years. Most patients developed ductal infiltrating carcinoma (IDC) of high grade (G3) (Supplementary Table S1).

To detect somatic mutations in DNA repair genes in breast and ovarian cancer samples, DNA was extracted from FFPE as described in Section “Materials and Methods.” The coding regions and exon–intron boundaries of the MMR gene MSH6, and HR/NHEJ genes RAD50, MRE11A, and RAD51 were screened by NGS.

The somatic mutational screening identified 45 different variants annotated by Ion Reporter 5.0.4. Among the variants, 20 were exonic and 25 were intronic; moreover, 19 variants were unique and 26 were reported in more than one patient. All exonic variants were single-nucleotide variations, in detail missense or synonymous.

The pathogenicity of each filtered variant was predicted using SIFT, PolyPhen-2, Grantham score, and MutationTaster2 prediction tools. For missense variants, the effect on protein structure was also evaluated using the online web server HOPE3 which collects structural information on the 3D protein structure, sequence annotations in UniProt, and predictions from DAS servers (Venselaar et al., 2010). The intronic variants were analyzed with Human Splicing Finder4, which predicts the effect of mutations on splicing signals (Desmet et al., 2009). Moreover, for each variant, an extensive literature revision and searching in the major clinical and genetic databases (dbSNP, ClinVar, LOVD, and COSMIC) was performed, to integrate in silico and functional reports for each variant.

After filtering, 17 variants were obtained. They are listed together with prediction tool scores in Table 2. The gene harboring the major number of variants was MSH6 followed by RAD50, MRE11A, and RAD51. Filtered variants were confirmed by Sanger Sequencing. Seven variants were confirmed in tumor tissues, while ten variants were not confirmed due to Sanger Sequencing limitations (frequency <10%). The variants confirmed by Sanger Sequencing were as follows: MSH6 p.T305T, MSH6 p.N345Y, MSH6 p.A729A, RAD50 p.D675D, RAD50p.R850C, RAD50c.3165-4 A>T, and MRE11A: c.1098+17 A>G.

Since variants with p-value >0.01 according to Ion Reporter Software were discarded, these variants are less likely to be false positive. All the variants were also assessed in lymphocyte DNA and five variants were germline and two were somatic. The remaining 10 variants were not detected in the germline, so were considered somatic.

The pathogenic or predicted pathogenic variants, along with the BRCA1 status and the effect on the protein structure predicted by HOPE are reported in Table 3. In this cohort of breast and ovarian tumors, four rare variants in MSH6, one variant in RAD50, one variant in MRE11A, and two variants in RAD51 have been identified. The two MSH6 variants, p.T1008I and p.R1334Q, were already reported as pathogenic (Castiglia et al., 2008; Wu et al., 2014); the other two variants, p.N345Y and p.R841K, are novel and predicted pathogenic. The RAD50 variant, p.R850C, is scored pathogenic by all the prediction tools interrogated, and is reported in dbSNP (rs181961360) and in ClinVar databases as unknown alteration. The MRE11A variant, p.S632F, is predicted pathogenic and is reported in COSMIC (Id: COSM5793819) in a breast cancer case. The RAD51 variants p.S26L and p.A262T have never been described before. Two out of eight pathogenic or predicted pathogenic somatic variants were in two BRCA1 variant carriers, five variants were found in three BRCA1wt patients, and one variant out was found in a BRCA1 mutated patient. So, 14% of the BRCA1 variant carriers, 25% of the BRCA1wt, and 12.5% of the BRCA1 mutated patients carry also a somatic mutation in this subset of DNA repair genes. Considering patients carrying BRCA1 variants and BRCA1 pathogenic mutations as a unique category, the distribution of somatic missense variants in MSH6, RAD50, MRE11A, and RAD51 seems not to be affected by BRCA1 status.

**DISCUSSION**

Deficiencies in DNA repair are likely to cause chromosomal instability that leads to cell malfunctioning and tumorigenesis. Genetic polymorphisms in DNA repair genes are very common, and several studies have demonstrated a significant association of these polymorphisms with cancer risk (Goode et al., 2002; Hung et al., 2005; Choudhury et al., 2014; Grundy et al., 2016; Das and Ghosh, 2017). Recently, different DNA repair pathways have been proposed to be jointly involved in cancer (Simonelli et al., 2016). Moreover, to evaluate the efficiency of DNA repair in breast tumor samples may be clinically relevant for therapy (Li et al., 2010; Timms et al., 2014). Particularly, defects in MMR genes are associated with a variety of cancers including sporadic breast cancer (Murata et al., 2005). In this study, we aimed to determine if BRCA1 partners involved in HR, NHEJ, and MMR may contribute to breast and ovarian cancer development.

Taking advantage of yeast genetics and considering the high level of functional conservation of DNA repair pathways between yeast and human, we expressed pathogenic and neutral BRCA1 missense variants in DNA repair yeast mutants to identify functional interaction between BRCA1 and DNA repair proteins (Mohammadi et al., 2015; Abugable et al., 2017). Importantly, this study has confirmed yeast as good system to evaluate the functional impact of clinically relevant BRCA1 missense variants because most pathogenic variants increased HR, gene reversion, or other effects (Caligo et al., 2009; Maresca et al., 2015; Thouvenot et al., 2016). Moreover, we demonstrated the DBS repair pathway and MSH6 protein are required so that BRCA1 missense variants could induce intra-chromosomal HR in yeast suggesting the involvement of BRCA1 in yeast DNA repair. Previously, human MMR gene MLH1 has been reported to potentially interfere with yeast MMR conferring a mutator phenotype (Shimodaira et al., 1998). Similarly, BRCA1 pathogenic variants could interfere with yeast DNA repair pathways leading to the formation of higher level of endogenous DNA damage that can stimulate both intra-chromosomal HR and gene reversion. In addition, it is possible that different variants (pathogenic or neutral) could functionally interact with specific

3http://www.cmbi.ru.nl/hope
4http://www.umd.be/HSF3/
### TABLE 2 | Variants of DNA repair genes identified in this study.

| Gene | Nt change | AA change | VAF (%) | Patient | dbSNP | gMAF | tMAF | SIFT | PolyPhen 2 | Grantham | MutationTaster2 | CLINVAR | Clinical significance | Origin |
|------|-----------|-----------|---------|---------|-------|------|------|------|------------|----------|-----------------|---------|----------------------|--------|
| MSH6 | c.915T>A  | p.T305T   | 35      | P122    |       |      |      |      | D         | PD       | 143.0           | P       | U                   | GERMLINE|
|      | c.1033A>T | p.N345Y   | 30      | P258    |       |      |      |      | D         | PD       | 145.0           | P       | PP                  | SOMATIC |
|      | c.1281C>T | p.Y427Y   | 4       | P1052   |       |      |      |      | D         | PD       | 145.0           | P       | PP                  | SOMATIC |
|      | c.2187G>T | p.A729A   | 27      | P534    |       |      |      |      | D         | PD       | 145.0           | P       | U                   | SOMATIC |
|      | c.2522G>A | p.R841K   | 9       | P881    |       |      |      |      | D         | D        | 26.0            | DC      | PP                  | SOMATIC |
|      | c.3023G>T | p.T1008I  | 3       | P1143   |       |      |      |      | D         | D        | 89.0            | DC      | P                   | SOMATIC |
|      | c.4001G>A | p.R1334Q  | 3.5     | P1002   | rs267608122 |    |      |      | D         | D        | 43.0            | DC      | P                   | SOMATIC |
| RAD50| c.451C>T  | p.L151L   | 4       | P1002   |       |      |      |      | T         | B        | 94.0            | DC      | U                   | SOMATIC |
|      | c.1185T>A | p.N396K   | 3       | P1143   |       |      |      |      | T         | B        | 94.0            | DC      | PB                  | SOMATIC |
|      | c.2025C>T | p.D675D   | 72      | P614    | rs34147928 |    |      |      | 0.016     | 0.0      | 0.0             | P       | B                   | GERMLINE|
|      | c.2548C>T | p.R850C   | 33      | P46     | rs181961360 |    |      |      | 0.001     | 0.0      | 0.0             | DC      | U                   | SOMATIC |
|      | c.3165-4A | –         | 71      | P258    | rs104895050 |    |      |      | 0.003     | 0.0      | 0.0             | B       | B                   | GERMLINE|
|      | c.3168A>G | p.E1066E  | 4       | P1052   |       |      |      |      | T         | B        | 94.0            | DC      | U                   | SOMATIC |
| MRE11A| c.1098+17A>G | –       | 45      | P385    | rs1805365 |    |      |      | 0.0539    | 0.00421 | 0.00421        | B       | B                   | GERMLINE|
|      | c.1895C>T | p.S632F   | 3       | P1052   |       |      |      |      | D         | PD       | 145.0           | P       | PP                  | SOMATIC |
| RAD51| c.77C>T   | p.S26L    | 4       | P1002   |       |      |      |      | D         | B        | 145.0           | DC      | PP                  | SOMATIC |
|      | c.784G>A  | p.A262T   | 5       | P1052   |       |      |      |      | D         | D        | 58.0            | DC      | PP                  | SOMATIC |

Variants with coverage ≥800X, MAF =1%, present in only one patient and within 20 bp from exon-intron junction were selected for further analysis. Nucleotide (Nt) and amino acid (AA) change, VAF (variant allele frequency), BRCA1 status, minor allele frequency (MAF) according to 1000 genomes (gMAF, global minor allele frequency; tMAF, minor allele frequency in Tuscany), prediction tools scores, putative clinical significance, and variant origin are reported. SIFT: D, damaging; T, tolerated; PolyPhen 2: D, damaging; PD, possibly damaging; B, benign; MutationTaster2: P, polymorphism; DC, disease causing; CLINVAR: P, Pathogenic; B, benign; U, unknown. Clinical significance: P, clearly pathogenic; PP, probably pathogenic; PB, probably benign; B, clearly benign; U, unknown.
**TABLE 3 | Pathogenic or predicted pathogenic somatic variants.**

| Gene  | Patient | BRCA1 status | VAF (%) | AA change   | Protein domain | HOPE                                                                 |
|-------|---------|--------------|---------|-------------|----------------|----------------------------------------------------------------------|
| MSH6  | P258    | Missense     | 30      | p.N345Y     | --             | The mutant residue is bigger than the wild-type; this might lead to bumps. The mutation introduces a more hydrophobic residue; this can result in loss of hydrogen bonds and/or disturb correct folding. |
| P881  | Missense | 9            | p.R841K | ATP binding mismatched DNA binding | The mutant residue is located in a domain that is important for binding of other molecules. Mutation of the residue might disturb this function. The mutant residue is smaller; this might lead to loss of interactions. |
| P1143 | WT      | 3            | p.T1008I| ATP binding mismatched DNA binding | The mutated residue is located in a domain that is important for binding of other molecules and in contact with residues in another domain. It is possible that the mutation disturb these contacts. The wild-type and the mutant residues differ in size and hydrophobicity. |
| P1002 | WT      | 3.5          | p.R1334Q| --          | --             | The charge of the wild-type residue will be lost; this can cause loss of interactions with other molecules or residues. The mutant residue is smaller; this might lead to loss of interactions. |
| RAD50 | P46     | MUT          | 33      | p.R850C     | ATPase         | The mutated residue is located in a domain that is important for the main activity of the protein. Mutation of this residue might disturb protein function. The wild-type and mutant residues differ in charge, size, and hydrophobicity. |
| MRE11A| P1052   | WT           | 3       | p.S632F     | Exonuclease    | The mutated residue is located in a domain that is important for the main activity of the protein. Mutation of the residue might disturb this function. The mutant residue is bigger; this might lead to bumps. The mutation introduces a more hydrophobic residue at this position. This can result in loss of hydrogen bonds and/or disturb correct folding. |
| RAD51 | P1002   | WT           | 4       | p.S26L      | DNA binding ATPase recombinase | The mutated residue is located in a domain that is important for the main activity of the protein and is located on the surface of the protein. Mutations at this site can disturb interactions with other molecules or with other domains. The mutant residue is located in a domain that is important for the main activity of the protein. The differences between the wild-type and mutant residue can disturb the core structure of this important domain and thereby affect the catalytic activity. |
| P1052 | WT      | 5            | p.A262T | --          | --             | The mutated residue is located in a domain that is important for the main activity of the protein. The differences between the wild-type and mutant residue can disturb the core structure of this important domain and thereby affect the catalytic activity. |

Somatic alterations classified as pathogenic or probably pathogenic variants according to the literature and the prediction tools interrogated. The effect of missense variants on protein structure, obtained from HOPE (http://www.cmbi.ru.nl/hope), is also reported. BRCA1 status: VUS, variants of unknown significance; MUT, pathogenic mutation; WT, wild type.
DNA repair genes and have differential effect when the specific function is lacking.

To address whether DNA repair genes may have a role in BRCA1 tumorigenesis, we performed a sequence analysis in tumor samples from HBOC patients carrying BRCA1 wt, BRCA1 mutations, or BRCA1 missense variants. We identified somatic variants in the MMR gene MSH6 and in the DSB repair genes RAD50, MRE11A, and RAD51. All genes have at least one rare pathogenic or predicted pathogenic variant. We found pathogenic or predicted pathogenic variants in 14% of BRCA1 missense variant carriers, in 25% of BRCA1 wt patients, and in 12.5% of BRCA1 mutation carriers; therefore, the distribution of these DNA repair variants seems not to be affected by BRCA1 status. Pathogenic or predicted pathogenic variants were identified in ≥15% of patients confirming the potential involvement of these DNA repair genes in the tumorigenesis process. Due to Sanger sequencing limitations, we were not able to confirm 10 somatic variants at low frequency obtained after filtering. These variants are not false positive according to the p-value supplied by Ion Reporter Software. To confirm this evidence, we randomly selected one of these variants (MSH6 p.R841K) and successfully confirmed it by Droplet Digital PCR.

Two pathogenic and two new predicted pathogenic missense variants were found in MSH6 gene. These variants were identified in patients carrying BRCA1wt (patient P1002 and P1143) or missense variant (patient P258, p.A1789T; patient P881, p.Q804H). Interestingly, the expression of the BRCA1 VUS p.A1789T (patient P258) increased gene reversion when MSH6 is deleted in our yeast assay. Notably, the expression of the BRCA1 neutral variants p.Y179C and p.N550H (patient P519) increased gene reversion in MSH2 deleted yeast strain; moreover, this patient has been shown to carry a MSH2 exon deletion (Maresca et al., 2015). These results, together with the high frequency of MSH2 somatic alterations previously observed in a subset of BRCA1 carriers suggest that MMR might be frequently impaired in breast cancer (Maresca et al., 2015). It is well known that mutations in MMR genes destabilize the genome and can increase cancer susceptibility and progression. Tumors harboring MMR defects are characterized by the accumulation of mutations at microsatellites repeat sequences (Peltomaki, 2001a,b; Hsieh and Yamane, 2008; Haraldsdottir et al., 2016). Probably, defects in the MMR not only could start malignant transformation but might contribute to a “mutator phenotype.” This condition could lead to the accumulation of genomic aberrations and/or mutations resulting in a more aggressive behavior of the tumor. Germline mutations in MSH6 are reported to be associated to breast cancer, but no extensive study on evaluation of MSH6 somatic mutations in breast tumor samples is reported (Ollier et al., 2015; Kraus et al., 2017). It has been reported that mutations in genes encoding for MRN, involved primarily in DNA DSB repair, can increase breast cancer risk (Damiola et al., 2014). Notably, the assessment of DSB repair by measuring RAD51 foci in breast tumor samples has been proposed as predictor of chemo-sensitivity (Asakawa et al., 2010). Here, we have identified a total of four pathogenic predicted variants located in RAD50, MRE11A, and RAD51 genes. Importantly, in the patients carrying these somatic variants, BRCA1 is mutated (patient P46) or wt (patients P1002 and P1052). Actually, tumor samples from patient P1052 carries two distinct variants one in MRE11A and one in RAD51, suggesting that also DSB repair may contribute to cancer development. Interestingly, all patients with BRCA1wt (P1143, P1002, and P1052) carry mutations in almost all genes analyzed; in particular, patient P1143 has both MSH6 and RAD50 mutated, patient P1002 has MSH6, RAD50, and MRE11A mutated and patient 1052 carries mutations in all four genes analyzed.

Importantly, the functional impact of missense variants found in these screening and located in MSH6, RAD50, MRE11A, and RAD51 gene, was assessed using bioinformatics tools, but it is not completely known if they are functionally linked with BRCA1. Novel assays need to be developed in yeast and/or other model systems to understand their effect DNA repair and functional implications on BRCA1 activity. Altogether, this study suggests that somatic missense variants in DNA repair genes, in particular in MMR pathway, may contribute to breast and ovarian tumor development. Anyhow, we did not find any correlation between BRCA1 status and these somatic DNA repair variants. These missense variants of DNA repair genes belonging to different pathways may also represent new putative therapeutic targets (Majidinia and Yousefi, 2017).

CONCLUSION

The evaluation of functional impact of somatic variants on protein function could be important also to identify novel therapeutic targets. Here, we have proposed a novel functional approach based on yeast as genetic system to fast evaluate the functional interaction between DNA repair pathways and BRCA1 status, in order to give a new clue for precision medicine strategies. Therefore, the exploitation of yeast genetics to evaluate which DNA pathway is required to BRCA1 variant to affect genome stability could be relevant for therapy; combining these data with available genetic data could help geneticists in risk management of BRCA1 VUS carriers (Milne and Antoniou, 2016). Straightforwardly, MMR affects gene reversion in yeast expressing BRCA1 mutated or BRCA1 missense variant, and MSH2 and MSH6 deleterious mutations were found in patients carrying BRCA1 variants. This aspect may strengthen yeast as model system to study functional interrelationship between DNA repair and BRCA1.

DATA AVAILABILITY

The datasets generated for this study can be found in the Catalogue of Somatic Mutations in Cancer (COSP45736).

AUTHOR CONTRIBUTIONS

SL, TC, and AL carried out yeast experiments, analyzed data, and performed statistical analysis. LM, LS, MT, AGal, and MC chose the DNA repair genes for somatic mutational screening. LM performed the NGS analysis and variant prioritization.
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2018.00397/full#supplementary-material

FIGURE S1 | Expression of human BRCA1 wt and missense variants in the RSY6wt and in DNA repair mutant strains of S. cerevisiae. BRCA1 was detected in the total protein extracts from yeast strains grown in galactose by Western blot analysis with anti-BRCA1 antibody. Extracts from yeast expressing BRCA1 wild-type and missense variants were loaded as indicated on the top of the figure. In blue extract were prepared from yeasts expressing neutral variants, in red form yeast expressing pathogenic variants, in green from the VUS-expressing yeast, and in black from BRCA1wt or negative control (vector pYES2). The level of BRCA1 was determined in all the strains used: RSY6, mre11Δ, rad50Δ, rad51Δ, and msh5Δ. Western blot analysis in msh2Δ strain was already reported (Maresca et al., 2015). Loading control was evaluated by detecting the level of PGK.

TABLE S1 | Histopathological and clinical features of patients. Histotype, grade and receptors status of the tumors are reported.

REFERENCES

Aboughle, A. A., Awad, D. A., Fleifel, D., Ali, M. M., El-Khamisy, S., and Elseafy, M. (2017). Personalised medicine: genome maintenance lessons learned from studies in yeast as a model organism. Adv. Exp. Med. Biol. 1007, 157–178. doi: 10.1007/978-3-319-60733-7_9

Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., et al. (2010). A method and server for predicting damaging missense mutations. Nat. Methods 7, 248–249. doi: 10.1038/nmeth0410-248

Asakawa, H., Koizumi, H., Koike, A., Takahashi, M., Wu, W., Iwase, H., et al. (2010). Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res. 12:R17. doi: 10.1186/bcr2486

Bak, S. T., Sakellariou, D., and Pena-Diaz, J. (2014). The dual nature of mismatch repair as antimutator and mutator: for better or for worse. Front. Genet. 5:287. doi: 10.3389/fgene.2014.00287

Bronzetti, G., Galli, A., and Della Croce, C. (1990a). Antimutagenic effects of chlorophyllin. Basic Life Sci. 52, 463–468. doi: 10.1007/978-1-4615-9561-8_51

Bronzetti, G., Morichetti, E., Della Croce, C., Del Carratore, R., Giornini, L., and Galli, A. (1990b). Vanadium: genetical and biochemical investigations. Mutagenesis 5, 293–295.

Caligo, M. A., Bonatti, F., Guidugli, L., Aretini, P., and Galli, A. (2009). A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. Hum. Mutat. 30, 123–133. doi: 10.1002/humu.20817

Carvalho, M. A., Marsillac, S. M., Karchin, R., Manoukian, S., Grist, S., Swaby, R. F., et al. (2007). Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 67, 1494–1501. doi: 10.1158/0008-5472.CAN-06-3297

Castiglia, D., Bernardini, S., Alvino, E., Pagani, E., De Luca, N., Falcinelli, S., et al. (2008). Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer 47, 614–624. doi: 10.1002/gcc.20567

Chae, Y. K., Anker, J. F., Carneiro, B. A., Chandra, S., Kaplan, J., Kalyan, A., et al. (2016). Genomic landscape of DNA repair genes in cancer. Oncotarget 7, 23312–23321. doi: 10.18632/oncotarget.81968

Chakraborty, U., and Alani, E. (2016). Understanding how mismatch repair proteins participate in the repair/anti-recombination decision. FEMS Yeast Res. 16:fov071. doi: 10.1093/femsyr/fov071

Choudhury, J. H., Choudhury, B., Kundu, S., and Ghosh, S. K. (2014). Combined effect of tobacco and DNA repair genes polymorphisms of XRCC1 and XRCC2 influence high risk of head and neck squamous cell carcinoma in northeast Indian population. Med. Oncol. 31:67. doi: 10.1007/s12032-014-0067-8

Couch, F. J., Rasmussen, L. J., Hofstra, R., Monteiro, A. N., Greenblatt, M. S., and de Wind, N. (2008). Assessment of functional effects of unclassified genetic variants. Hum. Mutat. 29, 1314–1326. doi: 10.1002/humu.20899

Damiola, F., Pertesi, M., Oliver, J., Le Calvez-Kelm, F., Voegele, C., Young, E. L., et al. (2014). Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res. 16:R58. doi: 10.1186/bcr3669

Das, R., and Ghosh, S. K. (2017). Genetic variants of the DNA repair genes from Exome Aggregation Consortium (EXAC) database: significance in cancer. DNA Repair 52, 92–102. doi: 10.1016/j.dnarep.2017.02.013

Desmet, F. O., Hamroun, D., Lalande, M., Colloid-Beroud, G., Claustres, M., and Beroud, C. (2009). Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 37:e67. doi: 10.1093/nar/gkp215

Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., et al. (1999). Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol. 9, 51–54. doi: 10.1016/S0960-9822(99)80047-5

Fanale, D., Amodeo, V., Corsini, L. R., Rizzo, S., Bazan, V., and Russo, A. (2012). Breast cancer genome-wide association studies: there is strength in numbers. Oncogene 31, 2121–2128. doi: 10.1038/onc.2011.406onc.2011408

Flores-Rozas, H., Jaafar, L., and Xia, L. (2015). The role of DNA mismatch repair and recombination in the processing of DNA alkylating damage in living yeast cells. Adv. Biosci. Biotechnol. 6, 408–418. doi: 10.4236/abb.2015.656040

Fu, Y. P., Yu, J. C., Cheng, T. C., Lou, M. A., Hsu, G. C., Wu, C. Y., et al. (2003). Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63, 2440–2446.

Galli, A., Vellosi, R., Fiorio, R., Della Croce, C., Del Carratore, R., Morichetti, E., et al. (1991). Genotoxicity of vanadium compounds in yeast and cultured mammalian cells. Teratog. Carcinog. Mutagen. 11, 175–183. doi: 10.1002/tcm.2170110402

Gietz, R. D., and Schiestl, R. H. (2007). High-efficiency yeast transformation using LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2, 31–34. doi: 10.1038/nprot.2007.13

Goode, E. L., Ulrich, C. M., and Potter, J. D. (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1513–1530.

Grantham, R. (1974). Amino acid difference formula to help explain protein evolution. Science 185, 862–864. doi: 10.1126/science.185.4154.862
Greenberg, R. A., Sobhian, B., Pathania, S., Cantor, S. B., Nakatani, Y., and Livingston, D. M. (2006). Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. *Genes Dev.* 20, 34–46. doi: 10.1101/gad.1381306

Groothuis, F. S., and Sixma, T. K. (2016). The conserved molecular machinery in DNA mismatch repair enzyme structures. *DNA Repair* 38, 14–23. doi: 10.1016/j.dnarep.2015.11.012

Grundy, A., Richardson, H., Schuetz, J. M., Burstyn, I., Spinnelli, J. J., Brooks-Wilson, A., et al. (2016). DNA repair variants and breast cancer risk. *Environ. Mol. Mutagen.* 57, 269–281. doi: 10.1002/em.22013

Haralddsottir, S., Roth, R., Pearlman, R., Hampel, H., Arnold, C. A., and Frankel, W. L. (2016). Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis. *Fam. Cancer* 15, 253–260. doi: 10.1007/s10689-015-9856-2

Hsieh, P., and Yamane, K. (2008). DNA mismatch repair: molecular mechanism, cancer, and ageing. *Mech. Ageing Dev.* 129, 391–407. doi: 10.1016/j.mad.2008.02.012S0047-6374(08)00064-X

Hung, R. J., Hall, J., Brennan, P., and Boffetta, P. (2005). Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. *Am. J. Epidemiol.* 162, 925–942. doi: 10.1093/aje/kwi318

Kowalczykowski, S. C. (2015). An overview of the molecular mechanisms of recombinational DNA repair. *Cold Spring Harb. Perspect. Biol.* 7:a016410. doi: 10.1101/cshperspect.a016410

Kraus, C., Hoyer, J., Vasilieou, G., Wunderle, M., Lux, M. P., Fasching, P. A., et al. (2017). Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes other than BRCA1/2. *Int. J. Cancer* 140, 95–102. doi: 10.1002/ijc.34042

Kumar, A., Majumdar, B., Dutta, G., Khandalwal, A., Mondal, S., et al. (2009). The twiddler’s plus syndrome—a case report. *Kardiol. Pol.* 67, 1105–1106.

Kwei, K. A., Kung, Y., Salari, K., Holcomb, I. N., and Pollack, J. R. (2010). Genomic instability in breast cancer: pathogenesis and clinical implications. *Mol. Oncol.* 4, 255–266. doi: 10.1016/j.molonc.2010.04.S1574-7891(10)00023-1

Li, S. X., Sjolund, A., Harris, L., and Sweasy, J. B. (2010). DNA repair and personalized breast cancer therapy. *Environ. Mol. Mutagen.* 51, 897–908. doi: 10.1002/em.20606

Lindor, N. M., Guidugli, L., Wang, X., Vallee, M. P., Monteiro, A. N., Tavtigian, S., et al. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Hum. Mutat.* 33, 8–21. doi: 10.1002/humu.21627

Liu, D., Keijzers, G., and Rasmussen, L. J. (2017). DNA mismatch repair and its many roles in eukaryotic cells. *Mutat. Res. Rev.* 773, 174–187. doi: 10.1016/j.mrrrev.2017.07.001

Lodovichi, M., Guidugli, L., Wang, X., Vallee, M. P., Monteiro, A. N., Tavtigian, S., et al. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Hum. Mutat.* 33, 8–21. doi: 10.1002/humu.21627

Liu, D., Keijzers, G., and Rasmussen, L. J. (2017). DNA mismatch repair and its many roles in eukaryotic cells. *Mutat. Res. Rev.* 773, 174–187. doi: 10.1016/j.mrrrev.2017.07.001

Lodovichi, M., Guidugli, L., Wang, X., Vallee, M. P., Monteiro, A. N., Tavtigian, S., et al. (2012). A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). *Hum. Mutat.* 33, 8–21. doi: 10.1002/humu.21627

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.

Majidinia, M., and Yousefi, B. (2005). Deficient DNA mismatch repair: a common etiologic factor for colon cancer. *Hum. Mol. Genet.* 10, 735–740.
Tavtigian, S. V., Greenblatt, M. S., Lesueur, F., and Byrnes, G. B. (2008b). In silico analysis of missense substitutions using sequence-alignment based methods. *Hum. Mutat.* 29, 1327–1336. doi: 10.1002/humu.20892

Thouvenot, P., Ben Yamin, B., Fourniere, L., Lescure, A., Boudier, T., Del Nery, E., et al. (2016). Functional assessment of genetic variants with outcomes adapted to clinical decision-making. *PLoS Genet.* 12:e1006096. doi: 10.1371/journal.pgen.1006096

Timms, K. M., Abkevich, V., Hughes, E., Neff, C., Reid, J., Morris, B., et al. (2014). Classification of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. *Breast Cancer Res.* 16:475. doi: 10.1186/s13058-014-0475-xs13058-014-0475-x

Vallee, M. P., Francy, T. C., Judkins, M. K., Babikyan, D., Lesueur, F., Gammon, A., et al. (2012). Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs. *Hum. Mutat.* 33, 22–28. doi: 10.1002/humu.21629

Venselaar, H., Te Beek, T. A., Kuipers, R. K., Hekkelman, M. L., and Vriend, G. (2010). Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics* 11:548. doi: 10.1186/1471-2105-11-548

Walker, L. C., Whiley, P. J., Houdayer, C., Hansen, T. V., Vega, A., Santamarina, M., et al. (2013). Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. *Hum. Mutat.* 34, 1424–1431. doi: 10.1002/humu.22388

Wang, Y., Cortez, D., Yashi, P., Neff, N., Elledge, S. J., and Qin, J. (2000). BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. *Genes Dev.* 14, 927–939.

Westmoreland, T. J., Olson, J. A., Saito, W. Y., Huper, G., Marks, J. R., and Bennett, C. B. (2003). Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast. *J. Surg. Res.* 113, 62–73. doi: 10.1016/S0022-4804(03)00155-0

Wu, G., Diaz, A. K., Paugh, B. S., Rankin, S. L., Ju, B., Li, Y., et al. (2014). The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. *Nat. Genet.* 46, 444–450. doi: 10.1038/ng.2938

Zimmermann, F. K. (1975). Procedures used in the induction of mitotic recombination and mutation in the yeast *Saccharomyces cerevisiae*. *Mutat. Res.* 31, 71–86. doi: 10.1016/0022-4853(75)90069-2

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Maresca, Lodovichi, Lorenzoni, Cervelli, Monaco, Spugnesi, Tincred, Falaschi, Zavoglia, Landucci, Roncella, Gadducci, Naccarato, Caligo and Galli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.